| Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. | |
| | |
MedLine Citation:
|
PMID: 21864075 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Phase I clinical trials exploring the use of autologous mesenchymal stem cell (MSC) therapy for the treatment of multiple sclerosis (MS) have begun in a number of centers across the world. MS is a complex and chronic immune-mediated and neurodegenerative disease influenced by genetic susceptibility and environmental risk factors. The ideal treatment for MS would involve both attenuation of detrimental inflammatory responses, and induction of a degree of tissue protection/regeneration within the CNS. Preclinical studies have demonstrated that both human-derived and murine-derived MSCs are able to improve outcomes in the animal model of MS, experimental autoimmune encephalomyelitis. How MSCs ameliorate experimental autoimmune encephalomyelitis is being intensely investigated. One of the major mechanisms of action of MSC therapy is to inhibit various components of the immune system that contribute to tissue destruction. Emerging evidence now supports the idea that MSCs can access the CNS where they can provide protection against tissue damage, and may facilitate tissue regeneration through the production of growth factors. The prospect of cell-based therapy using MSCs has several advantages, including the relative ease with which they can be extracted from autologous bone marrow or adipose tissue and expanded in vitro to reach the purity and numbers required for transplantation, and the fact that MSC therapy has already been used in other human disease settings, such as graft-versus-host and cardiac disease, with initial reports indicating a good safety profile. This article will focus on the theoretical and practical issues relevant to considerations of MSC therapy in the context of MS. |
| | |
Authors:
|
Peter J Darlington; Marie-Noëlle Boivin; Amit Bar-Or |
Related Documents
:
|
19735705 - Lipopolysaccharide triggers macrophage activation of inflammatory cytokine expression, ... 20588005 - Urinary bladder tissue engineering using natural scaffolds in a porcine model: role of ... 12819085 - Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppression. 19952355 - Lipid droplet formation in leprosy: toll-like receptor-regulated organelles involved in... 1281165 - Synergy between encephalitogenic t cells and myelin basic protein-specific antibodies i... 20399885 - Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of neurotherapeutics Volume: 11 ISSN: 1744-8360 ISO Abbreviation: Expert Rev Neurother Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-08-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101129944 Medline TA: Expert Rev Neurother Country: England |
Other Details:
|
Languages: eng Pagination: 1295-303 Citation Subset: IM |
Affiliation:
|
Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montréal, QC, Canada; Neuroimmunology Unit, Room 111, 3801 University Street, Montréal, QC, H3A 2B4, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical...
Next Document: Antiganglioside antibodies in Guillain-Barré syndrome and its related conditions.